Daiichi Sankyo
AstraZeneca partners with Daichii Sankyo in potential $6bn cancer drug deal
July 27, 2020Research and Development, Sales and Marketing AstraZeneca, Daiichi Sankyo, partnership, pharma
AstraZeneca and Daiichi Sankyo have joined forces to drive the development and commercialisation of the latter’s DS-1062, a trophoblast cell-surface …
Daiichi Sankyo’s Turalio becomes first FDA-approved therapy for rare tumour
August 5, 2019Sales and Marketing Cancer, Daiichi Sankyo, FDA, Turalio, US, pharma, rare cancer
Daiichi Sankyo has seen its CSF1R inhibitor Turalio (pexidartinib) approved by the FDA in the treatment of symptomatic tenosynovial giant …
Two Daiichi Sankyo drugs dealt a thumbs up and thumbs down by FDA advisory panel
May 15, 2019Research and Development, Sales and Marketing Daiichi Sankyo, FDA, pexidartinib, pharma, quizartinib
Daiichi Sankyo was left with a bittersweet taste in its mouth after it saw one of its drugs recommended for …
AstraZeneca and Daiichi Sankyo partner up for $6.9 billion cancer collaboration
March 29, 2019Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, Daiichi Sankyo, pharma
AstraZeneca and Daiichi Sankyo have announced a new collaboration agreement to the tune of potentially $6.9 billion which will see …
Daiichi Sankyo show positive results for atrial fibrillation treatment Lixiana
March 18, 2019Manufacturing and Production, Research and Development Daiichi Sankyo, Lixiana, pharma, vitamin K antagonist
Japanese firm Daiichi Sankyo has announced positive results of the first randomised controlled trial of uninterrupted Lixiana (edoxoban) in atrial …
Daiichi Sankyo: Two steps forward, one step back in cancer deals
December 14, 2017Sales and Marketing Daiichi Sankyo, biotech, drugs, pharma, pharmaceutical
Daiichi Sankyo had a busy day in terms of its deals in oncology, not only did it tear up its …
Daiichi settles undisclosed drug side-effects case for $300 million
August 2, 2017Research and Development, Sales and Marketing Benicar, Daiichi Sankyo, biotech, drugs, pharma, pharmaceutical
Daiichi Sankyo has settled a case alleging that it did not fully disclose adverse side-effects of its drug, Benicar, with …
Big success and even bigger failure for Daiichi Sankyo’s experimental therapy
July 3, 2017Research and Development, Sales and Marketing Daiichi Sankyo, mirogabalin
Daiichi Sankyo has been hit with mixed news this week regarding its experimental therapy mirogabalin. The drug posted trial success …
Daiichi pulls out of India with closure of 170-strong R&D plant
January 11, 2017Manufacturing and Production, Research and Development Daiichi Sankyo, Ranbaxy, Sun Pharma
Japanese pharma firm Daiichi Sankyo has announced its intention to close its R&D centre in Gurgaon, India, a step in …
Amgen agrees deal to commercialise biosimilars in Japan with Daiichi Sankyo
July 14, 2016Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Daiichi Sankyo, Japan, biosimilars
Amgen (NASDAQ: AMGN) has agreed a deal with Daiichi Sankyo (TSE: 4568) that will see the pair commercialise nine biosimilars …
UCB scores Japanese approval for seizure therapy, Vimpat
July 5, 2016Manufacturing and Production, Research and Development Daiichi Sankyo, Japan, UCB, japanese
UCB Biopharma (EURONEXT: UCB) and Daiichi Sankyo have announced that Vimpat (lacosamide) has been approved as an adjunctive therapy in …
Cell Therapy signs £12.5 million licensing deal with Daiichi Sankyo for heart failure treatment
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Daiichi Sankyo, Deals, cell therapy, heart failure, licensing
UK-based Cell Therapy on Tuesday said it has signed a £12.5 million licensing deal with Japan’s Daiichi Sankyo (TYO: 4568) …
Daiichi Sankyo names Antoine Yver global head of oncology research and development
April 1, 2016Business Services, Medical Communications Daiichi Sankyo, Japan, appointment
Japanese drug major Daiichi Sankyo (TYO: 4568) on Friday named Antoine Yver, global head, oncology research and development, effective April …
Daiichi Sankyo to expand access to clinical trial data
February 3, 2016Research and Development Daiichi Sankyo, R&D, clinical trials, open access, open data, transparency
Daiichi Sankyo has announced today that it will share clinical trial data to qualified researchers through an online web request …
Daiichi Sankyo rocked by further job losses
December 9, 2015Manufacturing and Production Daiichi, Daiichi Sankyo
The Japanese pharma firm Daiichi Sankyo is to close an antibody-producing subsidiary in Germany, as the company continues to cut …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
